IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 57
- Registration Number
- NCT02231762
- Locations
- 🇦🇹
Vienna General Hospital, Vienna, Austria
🇩🇪Charité University Hospital, Berlin, Germany
🇩🇪Zentralklinik Bad Berka, Bad Berka, Germany
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
- Conditions
- Acromegaly
- Interventions
- Other: SAGIT
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 71
- Registration Number
- NCT02231593
- Locations
- 🇫🇷
CHU Bicetre, Le Kremlin-Bicêtre, France
🇧🇷Federal University of Minas Gerais, Belo Horizonte, Brazil
🇧🇷Private practice, Saúde, Brazil
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 12
- Registration Number
- NCT02162446
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
- Conditions
- Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
- Interventions
- Biological: Botulinum toxin type A
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 212
- Registration Number
- NCT02106351
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 50
- Registration Number
- NCT02075606
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Maidstone Hospital, Maidstone, United Kingdom
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 146
- Registration Number
- NCT02057666
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Hospital of Ministry of Health, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke
- Conditions
- Lower Limb Spasticity
- Interventions
- Biological: Botulinum toxin type A
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 186
- Registration Number
- NCT02020980
- Locations
- 🇪🇸
Hospital Marítimo Oza, A Coruña, Spain
🇪🇸Hospital de Cruces, Bilbao, Spain
🇪🇸Hospital Dr Negrín, Las Palmas De G.C., Spain
Predictive Factors Study
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 5
- Registration Number
- NCT02020499
- Locations
- 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
- Conditions
- Acromegaly
- Interventions
- Other: Non-interventional cross-sectional survey
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 367
- Registration Number
- NCT02020967
- Locations
- 🇷🇺
Endocrinology Hospital at First Moscow State Medical University, Moscow, Russian Federation
🇷🇺Moscow Board of Health Endocrinology Dispensary, Moscow, Russian Federation
Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice
- Conditions
- Photodynamic Transurethral Resection of the Bladder (TUR-B)
- Interventions
- Drug: Hexvix
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 400
- Registration Number
- NCT02012036
- Locations
- 🇩🇪
Caritas-Krankenhaus St. Josef, Klinik fuer Urologie, Regensburg, Germany
🇩🇪Klinikverbund Südwest, Sindelfingen, Germany